Litcius/Paper detail

Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors

David Preiss, Jonathan A. Tobert, G. Kees Hovingh, Christina Reith

2020Journal of the American College of Cardiology75 citationsDOI

Topics & Concepts

MedicinePCSK9Hydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatinPharmacologyStatinLDL receptorCholesterolInternal medicineLipoproteinLipoproteins and Cardiovascular HealthPharmaceutical Economics and PolicyComputational Drug Discovery Methods
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors | Litcius